<DOC>
	<DOC>NCT01592890</DOC>
	<brief_summary>This single-center, open-label study will assess the excretion balance, pharmacokinetics and metabolism of oral [14C]-labeled RO4917523 in healthy male volunteers. Subjects will receive a single oral dose of [14C]-labeled RO4917523 and an intravenous tracer dose of [13C]-labeled RO4917523 on Day 1. In-clinic period will be up to 18 Days. Anticipated time on study is up to 15 weeks.</brief_summary>
	<brief_title>A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Male adults, 18 to 65 years of age inclusive Body mass index (BMI) 18.0 to 32.0 kg/m2 Healthy, as judged by a physician on the basis of a medical history, general physical examination, laboratory tests, vital signs and 12lead ECG Medical history without major pathology Agree to use two effective methods of contraception with their partners, including one barrier method (e.g. condom) throughout the study and for up to 3 months after the last dose of study drug History of relevant drug and or food allergies Smoking (within 60 days prior to drug administration until the followup visit) History of alcohol abuse or drug addiction (including soft drugs like cannabis products) Participation in a drug study within 60 days preceding first administration of study drug; participation in more than 3 other drug studies within 10 months preceding the first administration of study drug Infrequent bowel movements (less than once per 2 days) Participation in another ADME study with a radiation burden &gt;0,1 mSv in the period of 1 years before the start of the study Positive screen for drugs of abuse Average intake of more than 24 units of alcohol per week Positive for hepatitis B, hepatitis C or HIV infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>